Cart
sales@molnova.com
Home - Products - MAPK/ERK Signaling - ERK - Ulixertinib hydrochloride

Ulixertinib hydrochloride

CAS No. 1956366-10-1

Ulixertinib hydrochloride( —— )

Catalog No. M36325 CAS No. 1956366-10-1

Ulixertinib hydrochloride (Ulixertinib HCl) is an orally available, selective and potent ERK1/2 inhibitor with anticancer and antitumor activity that inhibits the NB cell cycle and promotes apoptosis, and may be used in the study of solid tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 69 Get Quote
10MG 100 Get Quote
25MG 158 Get Quote
50MG 233 Get Quote
100MG 338 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Ulixertinib hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Ulixertinib hydrochloride (Ulixertinib HCl) is an orally available, selective and potent ERK1/2 inhibitor with anticancer and antitumor activity that inhibits the NB cell cycle and promotes apoptosis, and may be used in the study of solid tumors.
  • Description
    Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    ERK
  • Recptor
    ERK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1956366-10-1
  • Formula Weight
    469.79
  • Molecular Formula
    C21H23Cl3N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (212.86 mM; Ultrasonic ) H2O : 0.1 mg/mL (0.21 mM; Ultrasonic (<80°C))
  • SMILES
    ClC1=C(C=2C=C(C(N[C@H](CO)C3=CC(Cl)=CC=C3)=O)NC2)C=C(NC(C)C)N=C1.Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Changwen Ning, et al. Targeting ERK Enhances the Cytotoxic Effect of the Novel PI3K and mTOR Dual Inhibitor VS-5584 in Preclinical Models of Pancreatic Cancer. Oncotarget. 2017 Jul 4;8(27):44295-44311.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • ASTX029

    ASTX029 is a selective and orally bioavailable extracellular signal-regulated kinases 1 and 2 (ERK 1/2) inhibitor, with potential antineoplastic activity.

  • NMDA

    N-Methyl-D-aspartic acid is an amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors.

  • VX-11e

    A potent, selective, and orally bioavailable inhibitor of ERK2 with Ki of <2 nM.

Sign In Join Free